View Author
scopus: 13002958100

Elzakker, P.M.M.L. van

(Pascal van Elzakker)


transduction t cells culture patient t lymphocytes lymphocytes rtvsup vector t-cell car t cells therapy clone transduced cancer figure phoenix x-fold x-fold bags protocol cultilife production number galv rcr assay lamer phoenix clone 58 cultilife bags epitope efficiency range retrovirus caix-car virus level receptor transduction efficiencies response erasmus mc retronectin † retronectin blood ampli cytolysis à196 1 c t cells transduced autologou à80 1 c transgene 293 cells treatment control donor medium peptide stability method transduced t cells dc-bag gene transduction table immunogene therapy antibody panel sequence erasmu anti-car serum titer result reactivity expression transduction efficiency volume speci galvpos 293 cells immunogene chain expansion cell carcinoma detection




7 Most Recent Publications

Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells (Article)
Lamers, C.H.J. Elzakker, P.M.M.L. van Steenbergen, S.L.C. van Luider, B.A. Groot, C. Krimpen, B.A. van Vulto, A.G. Sleijfer, S. Debets, J.E.M.A. Gratama, J-W.
2013-05-01
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells (Article)
Lamers, C.H.J. Willemsen, R.A. Elzakker, P.M.M.L. van Steenbergen-Langeveld, S. van Broertjes, M. Oosterwijk-Wakka, J. Oosterwijk, E. Sleijfer, S. Debets, J.E.M.A. Gratama, J-W.
2011-01-06
Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors (Article)
Lamers, C.H.J. Willemsen, R.A. Elzakker, P.M.M.L. van Gratama, J-W. Debets, J.E.M.A.
2009-04-01
Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield (Article)
Lamers, C.H.J. Elzakker, P.M.M.L. van Steenbergen, S.L.C. van Sleijfer, S. Debets, J.E.M.A. Gratama, J-W.
2008-07-21
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years (Article)
Lamers, C.H.J. Elzakker, P.M.M.L. van Luider, B.A. Steenbergen, S.L.C. van Sleijfer, S. Debets, J.E.M.A. Gratama, J-W.
2008-04-01
Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient’s T lymphocytes using a carboxy anhydrase IX-specific scFv transgene (Article)
Lamers, C.H.J. Elzakker, P.M.M.L. van Langeveld, S.C.L. Sleijfer, S. Gratama, J-W.
2006-12-01
Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer (Article)
Lamers, C.H.J. Willemsen, R.A. Elzakker, P.M.M.L. van Krimpen, B.A. van Gratama, J-W. Debets, J.E.M.A.
2005-11-01
  • rss icon RSS Publication Feed
  • foaf icon FOAF Profile